Received for publication February 28, 2007.
Revised May 9, 2007.
Accepted for publication May 9, 2007.

CJ-023,423 (N-[({2-[4-(2-ethyl-4, 6-dimethyl-1H-imidazo [4, 5-c] pyridin-1-yl) phenyl] ethyl} amino) carbonyl]-4-methylbenzenesulfonamide), a novel, potent and selective prostaglandin EP₄ receptor antagonist with antihyperalgesic properties

Abstract

The prostaglandin (PG) EP₄ receptor subtype is expressed by peripheral sensory neurons. Although a potential role of EP₄ receptor in pain has been suggested, a limited number of selective ligands have made it difficult to explore the physiological functions of EP₄ or its potential as a new analgesic target. Here, we describe the in vitro and in vivo pharmacology of a novel EP₄ receptor antagonist, CJ-023,423 (N-[({2-[4-(2-ethyl-4, 6-dimethyl-1H-imidazo [4, 5-c] pyridin-1-yl) phenyl] ethyl} amino) carbonyl]-4-methylbenzenesulfonamide). In vitro, CJ-023,423 inhibits [³H]-PGE₂ binding to both human and rat EP₄ receptors with K_i of 13 ± 4 nM and 20 ± 1 nM, respectively. CJ-023,423 is highly selective for the human EP₄ receptor over other human prostanoid receptor subtypes. It also inhibits PGE₂-evoked elevation in intracellular cAMP at the human and rat EP₄ receptors with pA2 of 8.3 ±0.03 nM and 8.2 ± 0.2 nM, respectively. In vivo, oral administration of CJ-023,423 significantly reduces thermal hyperalgesia induced by intraplantar injection of PGE₂ (ED₅₀ = 12.8 mg/kg). CJ-023,423 is also effective in models of acute and chronic inflammatory pain. CJ-023,423 significantly reduces mechanical hyperalgesia in the carrageenan model. Furthermore, CJ-023,423 significantly reverses complete Freund's adjuvant-induced chronic inflammatory pain response. Taken together, the present data indicate that CJ-023,423, a highly potent and selective antagonist of both human and rat EP₄ receptors, produces anti-hyperalgesic effects in animal models of inflammatory pain. Thus, specific blockade of the EP₄ receptor signaling may represent a novel therapeutic approach for the treatment of inflammatory pain.

Key words: CJ-023,423, DRG cells, EP4 receptor, PGE2, hyperalgesia, inflammatory pain

This article has been cited by other articles:

				D. Xu, S. E. Rowland, P. Clark, A. Giroux, B. Cote, S. Guiral, M. Salem, Y. Ducharme, R. W. Friesen, N. Methot, et al. MF63 [2-(6-Chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 754 - 763. [Abstract] [Full Text] [PDF]

				P. Clark, S. E. Rowland, D. Denis, M.-C. Mathieu, R. Stocco, H. Poirier, J. Burch, Y. Han, L. Audoly, A. G. Therien, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 425 - 434. [Abstract] [Full Text] [PDF]